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Summary Methods such as immunohistochemistry that have enhanced the detection of carcinoma cells in
bone marrow aspirates appear to be useful in identifying patients with aggressive tumours. To detect epithelial
cells in bone marrow aspirates from breast carcinoma patients, we used a pool of five different monoclonal
antibodies (MAbs), which recognise 100% of breast carcinomas, together with the alkaline phosphatase
method on cytospun cells obtained from sternum and iliac crest. Primary tumours were also analysed for the
expression of the c-erbB-1 and c-erbB-2 oncogene products, and of two differentiation-related markers and
laminin receptors. Immunoreactive cells were detected in the bone marrow of 62 of the 197 patients tested
(31%) without any correlation with clinical parameters such as tumour size or lymph node metastasis, whereas
a significant (P<0.01) correlation was found with enhanced monomeric laminin receptor expression in the
primary tumour. In fact, this receptor was expressed in respectively 63% and 38% of primary tumours from
patients with and without immunoreactive cells in the bone marrow aspirates. Thus, the presence of
immunoreactive cells in bone marrow correlates with the expression in the primary tumour of a marker of the
metastatic potential of the tumour, the 67 kDa laminin receptor.
Immunocytochemical methodologies involving specific anti-
bodies have demonstrated usefulness in detecting bone mar-
row micrometastases that are not detectable by conventional
methods (Dearnaley et al., 1981), and preliminary reports
support the relevance of these metastatic cells in predicting
tumour progression (Stahel et al., 1985). In a recent con-
ference on cancer micrometastases, a statistically significant
association between the disease-free survival of patients with
breast or colon carcinoma and the presence of cytokeratin-
positive cells in the bone marrow was reported (Riethmuller
& Johnson, 1992). Multivariate analysis of those cases also
indicated that bone marrow positivity is an independent
predictor of tumour progression, and no correlation between
tumour cells in the bone marrow and conventional prognos-
tic factors was found (Riethmuller & Johnson, 1992).
Early metastatic dissemination from the primary tumour to
bone marrow, not correlated to other variables indicative of
metastatic spread, might reflect differences in the biological
characteristics of these tumours, such as an abnormal expres-
sion of an oncogene or other molecule related to
invasiveness.
In a previous study, we investigated the presence of epi-
thelial cells in bone marrow biopsies from breast carcinoma
patients using a single monoclonal antibody (MAb) and
immunofluorescence assay (Porro et al., 1988). In an effort to
increase the sensitivity of the analysis and to standardise the
methodology to the most used one, we used a pool of five
MAbs (Tagliabue et al., 1986) in an enzymatic assay to study
197 bone marrow aspirates from breast carcinoma patients.
The biological characteristics of the primary tumours were
also investigated, in particular the expression of markers
related to tumour aggressiveness.
Materials and methods
Patients
Bone marrow aspiration from the sternum and the right and
left iliac crests was performed during surgery of the primary
tumour in 197 patients with primary breast carcinomas.
Peripheral blood was also collected (10 ml) immediately
before and after surgery from the first 61 patients. Clinical
and pathological information was obtained from the patient's
clinical record.
Immunocytochemistry
A mean volume of 4 ml of bone marrow, pooled from two or
three aspirations per site, was obtained. Bone marrow and
blood cells were separated by centrifugation on a Ficoll-
Hypaque density gradient and the interface cells were centri-
fuged on glass slides, fixed in cold acetone and stored at
- 70'C until tested. The immunocytochemistry test was per-
formed as previously described (Schlimok et al., 1987), using
the alkaline phosphatase technique with preformed com-
plexes of alkaline phosphatase and anti-alkaline phosphatase
MAb (Dakopatts, Denmark). For each aspiration site three
slides each containing 5 x 105 cells were tested, giving a total
of 45 x 105 bone marrow cells examined per patient. For
peripheral blood cell examination, three slides containing
cells harvested before surgery and three containing cells
harvested after were tested, a total of 3 x 106 cells.
Immunohistochemical analysis of the primary tumours was
carried out on frozen sections that were fixed in acetone and
stained using the immunoperoxidase method (Mariani-Cos-
tantini et al., 1984).
A pool of five different MAbs, including MBrl, MBr8,
MOv8, MOvl6 and MluCl, all directed against epithelial
membrane antigens related to epithelial differentiation (Tag-
liabue et al., 1986), and the CK-2 MAb (Boehringer-
Mannheim, Tutzing, Germany), which recognises the
cytokeratin component 18 present in simple epithelia, were
used for analysis of bone marrow cytospun cells.
For primary tumour characterisation, a separate set of
eight MAbs was used. MBrl and MBr8 are directed against
breast differentiation antigens (Mariani-Costantini et al.,
1984; Facheris et al., 1992). MGR1 and MGR2 are directed,
respectively, against the c-erbB-1 and the c-erbB-2 oncogene
products (Pellegrini et al., 1991; Tagliabue et al., 1991).
MluC5 is directed against the 67 kDa laminin receptor (Mar-
tignone et al., 1992). For integrin expression, the MAR4 and
MAR6 MAbs directed respectively against the PI and a6
subunits (Pellegrini et al., 1992; Bottini et al., 1993), and
OA54 MAb against the P4 subunit (Telios, CA), were tested.
All MAbs were used as purified immunoglobulins at a final
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concentration of 5 tLg ml '. Tumours were considered
positive when more than 10% of cells were reactive with the
tested MAb.
Results
The clinical characteristics of the 197 consecutive patients
with primary breast carcinoma examined in this study (Table
I) indicate a high prevalence of small tumours, with few or
no lymph node metastases and frequent hormone receptor
positivity, a picture that suggests good prognosis. Cases were
considered positive if at least one out of the three bone
marrow aspirates showed immunoreactivity with the pool of
MAbs selected for detection of epithelial cells. Of 197
patients examined, a total of 62 were positive, representing
21, 17 and 13% positivity in the sternum, right iliac crest and
left iliac crest aspirates respectively. In only 9% of patients
were all three samples positive, and 10% patients had two
positive samples.
Using the same immunochemical test to analyse peripheral
blood cells collected immediately before and after surgery in
61 patients revealed no immunoreactive cells in any of the
samples.
Fifty patients were then chosen based on their bone mar-
row positivity or negativity with the MAb pool and tested
with the anti-cytokeratin CK-2 MAb. Of the 25 pool-positive
samples, 21 contained cytokeratin-positive cells, whereas only
three of the 25 pool-negative cases were CK-2 positive. The
correlation between the reactivity of the two reagents is
highly statistically significant (P<0.001).
Statistical analysis to determine any association between
the presence of pool-immunoreactive cells in the bone mar-
row and other clinical and biological parameters (Table II)
indicated that bone marrow positivity was correlated with
tumour grade in that grade I tumours were almost all bone
marrow negative. For the other parameters, no significant
differences were found between the bone marrow-negative
and bone marrow-positive groups, although patients in the
latter group were more frequently lymph node positive, with
oestrogen and progesterone receptor-positive tumours of
small diameter and with a low proliferation rate.
The primary tumours were also analysed for the expression
of different markers related to differentiation and to
oncogene and adhesion receptor expression. The expression
Table I Distribution ofclinical and biological parameters in a series
of 197 patients with primary breast carcinoma
Parameter; Percentage of patients
Tumour size
TI 60
T2 29
T3 11
Histotype
Ductal 61
Mixed 30
Other 9
Lymph node infiltration
N- 51
NI-3 26
N>3 23
Tumour grade
I 13
II 66
III 21
Age (years)
<50 32
> 50 68
ER + 84
PGR + 66
LI + 68
aER, oestrogen receptor; PGR, progesterone receptor; LI, labelling
index. (Cut off for ER and PGR, 10 fmol mg-'; for LI, 2.8%.)
of the 6- and P4-integrin subunits was always superimposable,
whereas PI was found in almost all the tumours in a
homogeneous distribution. The only statistically significant
difference (P<0.01) between the bone marrow-positive and
bone marrow-negative group was in expression of the 67 kDa
laminin receptor in the primary tumours, enhanced expres-
sion being more frequent in the marrow-positive cases (Table
III). Less differentiated tumours (as indicated by MAb MBrl
and MBr8 non-reactivity) that overexpressed the c-erbB-1
oncogene product tended to be associated with the bone
marrow-positive group, whereas a borderline negative
association was found for c-erbB-2 overexpression, i.e.
tumours of the bone marrow-positive group were less fre-
quently positive for c-erbB-2 expression.
To investigate the prognostic significance of expression of
the 67 kDa laminin receptor in this patient series, this
parameter was analysed in association with some clinical and
biological parameters (Table IV). Indeed, the presence of this
receptor in the primary tumour was strongly associated with
lymph node metastasis (P<0.01), in addition to the associa-
tion with bone marrow positivity (Table III). No association
with other parameters was found.
Table II Association between bone marrow pool positivity and
other clinical and biological parameters
Percentage of patients
Parameter4 Bone marrow negative Bone marrow positive
Age <50 years
N+ 30 35
Ductal 49 56
TI 60 63
Grade I 17 5b
ER + 80 91
PGR + 63 69
LI + 72 61
aAbbreviations are as in Table I. bp = 0.05.
Table III Association between bone marrow positivity and marker
expression in primary tumour
Percentage of marker-positive patients
Bone marrow Bone marrow
Marker negative positive P
Ca-MBrl + 81 70
Ca-MBr8 + 68 55
c-erbB-l + 20 30 0.05
c-erbB-2 + 47 32
Laminin receptors +
67 kDa 38 63 <0.01
a6-subunit 42 54
Pi-subunit 85 82
p4-subunit 49 45
Table IV Characterisation of primary breast carcinomas according
to laminin receptor expression
Percentage of positive patients
Parameter' 67kDa negative 67kDa positive P
Age <50 years 31 34
Ti 61 62
Ductal 61 61
N + 37 65 <0.01
BM + 20 41 <0.01
ER + 83 84
PGR + 69 62
LI + 76 64
M6-subunit + 56 46
Pi-subunit + 83 87
P4-subunit + 50 47
aAbbreviations are as in Table I.1128 S. MENARD et al.
Discussion
Using a pool of MAbs directed against epithelial antigens, we
detected epithelial cells in the bone marrow from 31% of
patients with primary breast carcinomas. No immunoreactive
cells were found in the peripheral blood before or after
surgery, thus suggesting that bone marrow positivity is not
due to contamination by circulating tumour cells. In a
previous study (Porro et al., 1988; Salvadori et al., 1990),
using only one of these MAbs (MBrl) on cells isolated from
bone marrow biopsies, only 17% of the patients were found
to be positive, indicating that many positive cases were not
diagnosed. With the new pool tested on bone marrow
aspirates, the percentage of positive patients (31%) is very
similar to that reported by others on similar samples (Mansi
et al., 1987; Schlimok et al., 1987; Cote et al., 1988, 1991)
using different anti-epithelial reagents. The higher positivity
we found on aspirates vs biopsies could be due not only to
the use of a pool of MAbs instead of a single MAb, but also
to the gradient separation procedure of the cells from
aspirates, which might concentrate the tumour cells in the
sample. Our finding that the MAb pool-positive cases also
showed reactivity with the CK-2 anti-cytokeratin MAb,
which was the reagent used in two of the three other studies
(Schlimok et al., 1987; Ellis et al., 1989), together with the
similar percentage of positivity, strongly suggests that all of
these studies actually detect the same cell type and that the
prognostic significance described in two patient series (Dear-
naley et al., 1991; Riethmuller & Johnson, 1992) can prob-
ably be extended to the other studies. The follow-up of our
patient series now in progress should clarify this issue.
Consistent with observations in the other studies, we found
that the presence of positive cells in the bone marrow of our
patients is independent of other clinical parameters indicative
of the stage of disease, such as tumour size and lymph node
metastasis (Riethmuller & Johnson, 1992), but correlates with
the tumour grade; indeed, well-differentiated tumours as also
evaluated by marker expression had immunoreactive cells in
the bone marrow less frequently. Further, the laminin recep-
tor is more frequently expressed in the primary tumours of
patients with bone marrow spread than in those patients with
no epithelial cells detectable in the marrow. This receptor,
also associated with lymphatic spread, appears to identify
tumours with metastatic potential, independent of the site of
origin; the prognostic relevance of laminin receptor expres-
sion in breast carcinomas has recently been defined on a
series of 1,150 patients (Martignone et al., 1993). It remains
to establish whether finding epithelial cells in the bone
marrow adds to the prognostic value of laminin receptor
expression. The mechanism of action of the 67 kDa laminin
receptor is still unknown, but is probably not limited to
laminin binding. Indeed, the expression of other laminin
receptors such as a6/P1 (VLA-6) and a6/P4 seems to be
unrelated to metastatic spread. On the contrary, a6-subunit
expression is reported to decrease during tumour progression
(Zutter et al., 1993) and the x6-subunit may behave as a
tumour-suppressor gene (Sager et al., 1993).
The borderline negative correlation between overexpression
of the c-erbB-2 oncogene and bone marrow reactivity was
unexpected. In fact, the oncogene-positive tumours, which
have been associated with poor prognosis, were more fre-
quently negative at the bone marrow level. Consistent with
this observation is the recent finding of a peculiar metastatic
distribution of c-erbB-2-positive breast carcinomas, which
induce bone metastasis less frequently than the negative ones
(Kallioniemi et al., 1991).
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